This is a translation of the Swedish press release published 2022-09-08, 08:00 CET
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.
The board of directors of Neola Medical (publ) (”Neola Medical” or the ”Company”) has today, subject to approval by an extraordinary general meeting, resolved on a new issue of shares with preferential rights for existing shareholder of approximately SEK 55 million (the ”Rights Issue”). The purpose of the Rights Issue is to finance the Company’s continued development of Neola®, including technical and clinical validation studies, regulatory processes, other commercial preparations for market launch in the U.S. and Europe, and continued work to strengthen the patent portfolio. The Rights Issue is subject to approval by an Extraordinary General Meeting to be held on 27 September 2022 (“Extraordinary General Meeting”). Notice of the Extraordinary General Meeting will be published in a separate press release. Approximately 80 percent of the Rights Issue is covered by subscription and guarantee commitments. Certain existing shareholders have entered into subscription commitments, amongst others ANMIRO AB and Pär Josefsson (private and via company), and members of the Company’s board of directors and management team, including amongst others CEO Hanna Sjöström and chairman of the board Märta Lewander Xu. Furthermore, guarantee commitments have been provided by the existing shareholder ANMIRO AB, Pär Josefsson (via company) and Bengt Nevsten as well as the external investor LMK Venture Partners AB.
Read the translation of the Swedish press release in full here: Translation of Swedish press release
This information is information that Neola Medical is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 CET on 8 September 2022.